xiaochan的个人主页 - 老虎社区

xiaochan

暂无个人介绍

IP属地：未知

315关注

32粉丝

0主题

0勋章

2021-12-02

It’s in the app. Under “analysis”

@Ceddy:$Tiger Brokers(TIGR)$can someone analysis the short margin and short rate?

2021-08-19

是的

@炒股就是炒预期:$老虎证券(TIGR)$ 今晚不跳，明天必上17

2021-04-03

[得意] //@JLX:Bought!

A Moment Out of Favor Makes AMD A Must-Buy Growth Stock

2021-04-01

[财迷] [财迷] [财迷] [财迷] //@JLX:Check out all stocks related to Ev

Biden Infrastructure Plan Could Be Boon For These EV Stocks

2021-03-26

Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷] [财迷] [财迷] [比心] [比心] [比心]

抱歉，原内容已删除

2021-02-08

[得意]

Moderna Gets Added to Southeast Asia’s Vaccine Arsenal

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3570343633899015,"uuid":"3570343633899015","gmtCreate":1609950087068,"gmtModify":1609950087068,"name":"xiaochan","pinyin":"xiaochan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":32,"headSize":315,"tweetSize":318,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":603155467,"gmtCreate":1638378206090,"gmtModify":1638378206697,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It’s in the app. Under “analysis”","listText":"It’s in the app. Under “analysis”","text":"It’s in the app. Under “analysis”","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603155467","repostId":"603152283","repostType":1,"repost":{"id":603152283,"gmtCreate":1638378053907,"gmtModify":1638378054019,"author":{"id":"3574753638076287","authorId":"3574753638076287","name":"Ceddy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>can someone analysis the short margin and short rate?","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>can someone analysis the short margin and short rate?","text":"$Tiger Brokers(TIGR)$can someone analysis the short margin and short rate?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603152283","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":831697045,"gmtCreate":1629309343587,"gmtModify":1633685797077,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"是的","listText":"是的","text":"是的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831697045","repostId":"831845481","repostType":1,"repost":{"id":831845481,"gmtCreate":1629303917443,"gmtModify":1633685816047,"author":{"id":"3561619960620770","authorId":"3561619960620770","name":"炒股就是炒预期","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 今晚不跳，明天必上17","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 今晚不跳，明天必上17","text":"$老虎证券(TIGR)$ 今晚不跳，明天必上17","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831845481","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":340536334,"gmtCreate":1617428891428,"gmtModify":1634520988821,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Bought!","listText":"[得意]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Bought!","text":"[得意] //@JLX:Bought!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/340536334","repostId":"1113135434","repostType":4,"repost":{"id":"1113135434","pubTimestamp":1617351698,"share":"https://www.laohu8.com/m/news/1113135434?lang=&edition=full","pubTime":"2021-04-02 16:21","market":"us","language":"en","title":"A Moment Out of Favor Makes AMD A Must-Buy Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1113135434","media":"investorplace","summary":"It wasn’t that long ago thatAdvanced Micro Devices(NASDAQ:AMD) looked like it wouldn’t even survive,","content":"<p>It wasn’t that long ago that<b>Advanced Micro Devices</b>(NASDAQ:<b><u>AMD</u></b>) looked like it wouldn’t even survive, let alone thrive. A few years later though and this stock has been a life-changing holding for some investors. AMD stock has gone from $2 in 2016 to almost $100 in January of 2021.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49d2d17a48ac9f1f61c9ed51f5147b05\" tg-width=\"300\" tg-height=\"169\"><span>Source: Fabio Alcini / Shutterstock.com</span></p>\n<p>For investors that don’t understand this industry, they may think this run is being fueled by some sort of easy-money policy at the Federal Reserve. Where dovish monetary policy is helping to drive a disconnect from reality and fueling a period of overvaluation.</p>\n<p>Actions from the Fed certainly help the bull market. However, that isn’t the reason AMD stock has had such success. No, that’s been the strong leadership from management and the company’s market share.</p>\n<p>As of now, there’s no reason to bet on that changing anytime soon.</p>\n<p>Don’t Underestimate AMD</p>\n<p>Day by day, technology becomes more powerful. Graphics get better, speeds get quicker and users demand more from their products. Whether that user is an at-home gamer on a PC or a data scientist mining millions (or billions) of pieces of information.</p>\n<p>To make these tasks a reality, a company like Advanced Micro Devices is needed. The company’s graphics processing units (GPUs) have improved considerably in the past few years. Coupled with a tightly-run ship andtaking market share from its competition, the company has vaulted toward the top of its industry.</p>\n<p>The question then becomes, is its move higher sustainable? I believe the answer is yes.</p>\n<p>AMD has secular growth driving its business right now. After a robust 2020, consensus expectations call for another strong year in 2021. Analysts expect revenue to jump 38% to $13.5 billion and for earnings to grow 53% to $1.97 a share.</p>\n<p>At roughly $80 a share, that values AMD stock at about 40 times forward earnings. That might get some bemoaning from the value crowd, but this is a high-growth stock. Its valuation (at least based on profit) has been higher than this in the past and that hasn’t slowed the stock’s run at all.</p>\n<p>Plus consider its forward estimates, which call for 28% earnings growth in 2022. On the revenue front, analysts expect roughly 15% growth next year and18% growth in the following year.</p>\n<p>Forward estimates are tough to get a handle on — particularly for this group. The market previously underestimated AMD bya wide, wide margin&nbsp;as the company ultimately saw a<i>huge</i>pull-forward in business in 2020.</p>\n<p>Let’s put it this way. Its 2020 results ended up beating what analysts expected in 2021.It was a huge year.</p>\n<p>And now analysts expect almost 40% revenue growth this year. Who’s to say estimates for 2022 and 2023 aren’t too conservative?</p>\n<p>Breaking Down AMD Stock</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8312cf07a874752c276278271f9eca14\" tg-width=\"300\" tg-height=\"196\"><span>Source: Chart courtesy ofTrendSpider</span></p>\n<p>Advanced Micro Devices is years ahead of where the market thought it would be a few years ago. To say it hasn’t been priced like that wouldn’t be fair. However, it wouldn’t be fair to say that AMD stock has rallied far too much either.</p>\n<p>The stock is up about 100% over the past 12 months, but that figure is cherry-picked, because it comes right off the 2020 lows. From the pre-coronavirus 2020 highs, shares are up “just” 32%.Further, AMD is flat over the last six months and actually<i>down 15%so far this year</i>.</p>\n<p>That’s despite all of the extra growth AMD has harnessed over the past 12 months.</p>\n<p>For long-term bulls looking to buy intoattractive secular growth themes, AMD stock is a must-buy holding. Then you take into consideration all that CEO Lisa Su has done and the entity becomes even more attractive.</p>\n<p>The company has bolstered its assets and notably reduced its debt. This balance sheet overhaul has allowed Advanced Micro to drop $35 billion on a big acquisition. Granted, it’s an all-stock deal, not cash, but without the company’s financial improvements, AMD would have never been able to make the move.</p>\n<p>Further, managementexpects the deal to be“immediately accretive to AMD margins, cash flow and EPS.”</p>\n<p>That’s great news, because an improvement to its margins have already allowed the bottom line to expand considerably, while free cash flow has surged in the right direction.Everything the company is doing should have bulls’ attention right now.</p>\n<p>Currently down over 20% from the highs, I would be a buyer of the current dip.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Moment Out of Favor Makes AMD A Must-Buy Growth Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Moment Out of Favor Makes AMD A Must-Buy Growth Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-02 16:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/a-moment-out-of-favor-makes-amd-a-must-buy-growth-stock/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It wasn’t that long ago thatAdvanced Micro Devices(NASDAQ:AMD) looked like it wouldn’t even survive, let alone thrive. A few years later though and this stock has been a life-changing holding for some...</p>\n\n<a href=\"https://investorplace.com/2021/04/a-moment-out-of-favor-makes-amd-a-must-buy-growth-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://investorplace.com/2021/04/a-moment-out-of-favor-makes-amd-a-must-buy-growth-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113135434","content_text":"It wasn’t that long ago thatAdvanced Micro Devices(NASDAQ:AMD) looked like it wouldn’t even survive, let alone thrive. A few years later though and this stock has been a life-changing holding for some investors. AMD stock has gone from $2 in 2016 to almost $100 in January of 2021.\nSource: Fabio Alcini / Shutterstock.com\nFor investors that don’t understand this industry, they may think this run is being fueled by some sort of easy-money policy at the Federal Reserve. Where dovish monetary policy is helping to drive a disconnect from reality and fueling a period of overvaluation.\nActions from the Fed certainly help the bull market. However, that isn’t the reason AMD stock has had such success. No, that’s been the strong leadership from management and the company’s market share.\nAs of now, there’s no reason to bet on that changing anytime soon.\nDon’t Underestimate AMD\nDay by day, technology becomes more powerful. Graphics get better, speeds get quicker and users demand more from their products. Whether that user is an at-home gamer on a PC or a data scientist mining millions (or billions) of pieces of information.\nTo make these tasks a reality, a company like Advanced Micro Devices is needed. The company’s graphics processing units (GPUs) have improved considerably in the past few years. Coupled with a tightly-run ship andtaking market share from its competition, the company has vaulted toward the top of its industry.\nThe question then becomes, is its move higher sustainable? I believe the answer is yes.\nAMD has secular growth driving its business right now. After a robust 2020, consensus expectations call for another strong year in 2021. Analysts expect revenue to jump 38% to $13.5 billion and for earnings to grow 53% to $1.97 a share.\nAt roughly $80 a share, that values AMD stock at about 40 times forward earnings. That might get some bemoaning from the value crowd, but this is a high-growth stock. Its valuation (at least based on profit) has been higher than this in the past and that hasn’t slowed the stock’s run at all.\nPlus consider its forward estimates, which call for 28% earnings growth in 2022. On the revenue front, analysts expect roughly 15% growth next year and18% growth in the following year.\nForward estimates are tough to get a handle on — particularly for this group. The market previously underestimated AMD bya wide, wide margin as the company ultimately saw ahugepull-forward in business in 2020.\nLet’s put it this way. Its 2020 results ended up beating what analysts expected in 2021.It was a huge year.\nAnd now analysts expect almost 40% revenue growth this year. Who’s to say estimates for 2022 and 2023 aren’t too conservative?\nBreaking Down AMD Stock\nSource: Chart courtesy ofTrendSpider\nAdvanced Micro Devices is years ahead of where the market thought it would be a few years ago. To say it hasn’t been priced like that wouldn’t be fair. However, it wouldn’t be fair to say that AMD stock has rallied far too much either.\nThe stock is up about 100% over the past 12 months, but that figure is cherry-picked, because it comes right off the 2020 lows. From the pre-coronavirus 2020 highs, shares are up “just” 32%.Further, AMD is flat over the last six months and actuallydown 15%so far this year.\nThat’s despite all of the extra growth AMD has harnessed over the past 12 months.\nFor long-term bulls looking to buy intoattractive secular growth themes, AMD stock is a must-buy holding. Then you take into consideration all that CEO Lisa Su has done and the entity becomes even more attractive.\nThe company has bolstered its assets and notably reduced its debt. This balance sheet overhaul has allowed Advanced Micro to drop $35 billion on a big acquisition. Granted, it’s an all-stock deal, not cash, but without the company’s financial improvements, AMD would have never been able to make the move.\nFurther, managementexpects the deal to be“immediately accretive to AMD margins, cash flow and EPS.”\nThat’s great news, because an improvement to its margins have already allowed the bottom line to expand considerably, while free cash flow has surged in the right direction.Everything the company is doing should have bulls’ attention right now.\nCurrently down over 20% from the highs, I would be a buyer of the current dip.","news_type":1},"isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":357890286,"gmtCreate":1617253722945,"gmtModify":1634521781400,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Check out all stocks related to Ev&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Check out all stocks related to Ev&nbsp;","text":"[财迷] [财迷] [财迷] [财迷] //@JLX:Check out all stocks related to Ev","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/357890286","repostId":"1138291357","repostType":4,"repost":{"id":"1138291357","pubTimestamp":1617248516,"share":"https://www.laohu8.com/m/news/1138291357?lang=&edition=full","pubTime":"2021-04-01 11:41","market":"us","language":"en","title":"Biden Infrastructure Plan Could Be Boon For These EV Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1138291357","media":"yahoo","summary":"The plan, which the president will unveil today in Pittsburgh, also includes an initiative on renewable energy and the electric grid as part of a broad goal to supercharge the economy and fight climate change.In particular, it earmarks $174 billion for electric-vehicle efforts, such as EV rebates, charging ports and electric school buses.Biden's plan will \"enable automakers to spur domestic supply chains from raw materials to parts, retool factories to compete globally and support American worke","content":"<p>President Joe Biden's $2.5 trillion infrastructure plan calls for massive investments in electric vehicles and related technologies, a potential boon for EV stocks like<b>Tesla</b>(TSLA) as well as charging station operators<b>ChargePoint</b>(CHPT) and<b>Blink Charging</b>(BLNK).</p><p>The plan, which the president will unveil today in Pittsburgh, also includes an initiative on renewable energy and the electric grid as part of a broad goal to supercharge the economy and fight climate change.</p><p>In particular, it earmarks $174 billion for electric-vehicle efforts, such as EV rebates, charging ports and electric school buses.</p><p>Biden's plan will \"enable automakers to spur domestic supply chains from raw materials to parts, retool factories to compete globally and support American workers to make batteries and EVs,\" according to afact sheeton WhiteHouse.gov.</p><p>EV Stocks: Tax Credit Benefits</p><p>Biden is asking Congress to keep tax incentives that encourage motorists and add point-of-sale rebates to buy EVs. Currently, consumers can claim tax credits of as much as $7,500 when they buy an electric car.</p><p>But Tesla and<b>General Motors</b>(GM) have already passed the 200,000 limit at which point carmakers no longer qualify for the rebates.</p><p>Wedbush analyst Daniel Ives says he expects the ceiling will be lifted. He adds that an expansion of the tax credits to the $10,000 range or potentially higher in a tiered system is possible.</p><p>EV Initiatives: Infrastructure</p><p>There are about 41,400 EV charging stations in the U.S., according to the Department of Energy, though one station can have multiple ports that can serve several cars at a time. That compares with more than 136,400 gas stations, according to GasBuddy.</p><p>Biden's plan will establish grant and incentive programs for state and local governments and the private sector to build a national network of 500,000 EV chargers by 2030.</p><p>Ives calls this part of the plan a linchpin of these EV initiatives. \"Today there are roughly 100,000 public charging ports with another 300,000/400,000 needed over the next decade to support this groundswell EV green tidal wave for consumers/trucking.\"</p><p>Biden's plan also calls for the replacement of 50,000 diesel transit vehicles and electrification of at least 20% of school buses. It looks to also electrify the federal fleet, including the United States Postal Service.</p><p>EV Stocks</p><p>Tesla jumped 5.1% to 667.93 on thestock market today. TSLA stock has lost more than a quarter of its value since skyrocketing to an all-time high of 900.40 intraday on Jan. 25.</p><p>The company is also expected to report Q4 deliveries later this week. Wall Street expects deliveries of 174,000 vehicles.</p><p>Meanwhile, ChargePoint surged 19%. Blink Charging stock soared 11. And<b>Climate Change Crisis Rea</b>l (CLII), a blank check company that is taking EVgo public, rose 3%.</p><p>But legacy auto giants making a big push in EVs were down.GM stockslipped 1.8%,<b>Ford</b>(F) fell 1.7%, and German automaker<b>Volkswagen</b>(VWAGY) sank 3.8%.</p><p>Even newly public EV stocks were relatively muted.<b>Canoo</b>(GOEV) fell 2.9%,<b>Lordstown</b>(RIDE) rose 1.6%, and<b>Fisker</b>(FSR) advanced 3%.</p>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden Infrastructure Plan Could Be Boon For These EV Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden Infrastructure Plan Could Be Boon For These EV Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-01 11:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/ev-stocks-winner-biden-infrastructure-plan-174-billion-investment/?src=A00220><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>President Joe Biden's $2.5 trillion infrastructure plan calls for massive investments in electric vehicles and related technologies, a potential boon for EV stocks likeTesla(TSLA) as well as charging ...</p>\n\n<a href=\"https://www.investors.com/news/ev-stocks-winner-biden-infrastructure-plan-174-billion-investment/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLNK":"Blink Charging","F":"福特汽车","GOEV":"Canoo Inc.","VWAGY":"大众汽车ADR","TSLA":"特斯拉","CHPT":"ChargePoint Holdings Inc."},"source_url":"https://www.investors.com/news/ev-stocks-winner-biden-infrastructure-plan-174-billion-investment/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138291357","content_text":"President Joe Biden's $2.5 trillion infrastructure plan calls for massive investments in electric vehicles and related technologies, a potential boon for EV stocks likeTesla(TSLA) as well as charging station operatorsChargePoint(CHPT) andBlink Charging(BLNK).The plan, which the president will unveil today in Pittsburgh, also includes an initiative on renewable energy and the electric grid as part of a broad goal to supercharge the economy and fight climate change.In particular, it earmarks $174 billion for electric-vehicle efforts, such as EV rebates, charging ports and electric school buses.Biden's plan will \"enable automakers to spur domestic supply chains from raw materials to parts, retool factories to compete globally and support American workers to make batteries and EVs,\" according to afact sheeton WhiteHouse.gov.EV Stocks: Tax Credit BenefitsBiden is asking Congress to keep tax incentives that encourage motorists and add point-of-sale rebates to buy EVs. Currently, consumers can claim tax credits of as much as $7,500 when they buy an electric car.But Tesla andGeneral Motors(GM) have already passed the 200,000 limit at which point carmakers no longer qualify for the rebates.Wedbush analyst Daniel Ives says he expects the ceiling will be lifted. He adds that an expansion of the tax credits to the $10,000 range or potentially higher in a tiered system is possible.EV Initiatives: InfrastructureThere are about 41,400 EV charging stations in the U.S., according to the Department of Energy, though one station can have multiple ports that can serve several cars at a time. That compares with more than 136,400 gas stations, according to GasBuddy.Biden's plan will establish grant and incentive programs for state and local governments and the private sector to build a national network of 500,000 EV chargers by 2030.Ives calls this part of the plan a linchpin of these EV initiatives. \"Today there are roughly 100,000 public charging ports with another 300,000/400,000 needed over the next decade to support this groundswell EV green tidal wave for consumers/trucking.\"Biden's plan also calls for the replacement of 50,000 diesel transit vehicles and electrification of at least 20% of school buses. It looks to also electrify the federal fleet, including the United States Postal Service.EV StocksTesla jumped 5.1% to 667.93 on thestock market today. TSLA stock has lost more than a quarter of its value since skyrocketing to an all-time high of 900.40 intraday on Jan. 25.The company is also expected to report Q4 deliveries later this week. Wall Street expects deliveries of 174,000 vehicles.Meanwhile, ChargePoint surged 19%. Blink Charging stock soared 11. AndClimate Change Crisis Real (CLII), a blank check company that is taking EVgo public, rose 3%.But legacy auto giants making a big push in EVs were down.GM stockslipped 1.8%,Ford(F) fell 1.7%, and German automakerVolkswagen(VWAGY) sank 3.8%.Even newly public EV stocks were relatively muted.Canoo(GOEV) fell 2.9%,Lordstown(RIDE) rose 1.6%, andFisker(FSR) advanced 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":356963142,"gmtCreate":1616749184486,"gmtModify":1634524210055,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[比心]&nbsp;[比心]&nbsp;[比心]&nbsp;","listText":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[比心]&nbsp;[比心]&nbsp;[比心]&nbsp;","text":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷] [财迷] [财迷] [比心] [比心] [比心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/356963142","repostId":"1147585149","repostType":2,"isVote":1,"tweetType":1,"viewCount":437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":389262038,"gmtCreate":1612778867224,"gmtModify":1703764880427,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389262038","repostId":"1126813487","repostType":4,"repost":{"id":"1126813487","pubTimestamp":1612776380,"share":"https://www.laohu8.com/m/news/1126813487?lang=&edition=full","pubTime":"2021-02-08 17:26","market":"us","language":"en","title":"Moderna Gets Added to Southeast Asia’s Vaccine Arsenal","url":"https://stock-news.laohu8.com/highlight/detail?id=1126813487","media":"Bloomberg","summary":"Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to th","content":"<p>Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.</p>\n<p>Shots by&nbsp;AstraZeneca Plc,Pfizer Inc.-BioNTech SEandSinovac Biotech Ltd.have also been approved by at least one country in the region as inoculations roll out. China and India are giving somefreevaccines to countries like the Philippines, Myanmar and Cambodia.</p>\n<p>Indonesia, Southeast Asia’s biggest and most populous economy,startedits coronavirus vaccination program on Jan. 13, with President Joko Widodo taking thefirst Sinovac jab. More than 784,000 people have received their first dose.</p>\n<p>Wealthier but smaller Singapore -- the first in Southeast Asia to start an official Covid-19 vaccination program -- began inoculatinghealthcareworkers with the Pfizer shot on Dec. 30 and has given the first shot to more than 175,000 people since then. Its prime minister got his first dose on Jan. 8 and has also received his second shot.</p>\n<p>Strategies are evolving across the region as different supply deals are sealed. In the Philippines, President Rodrigo Duterte has said he will take a Russian or Chinese vaccine, but his government’s first approval was for the Pfizer shot.</p>\n<p>Indonesia, which is battling the worst outbreak in Southeast Asia, ended 2020 by switching up who’s on its priority list for shots -- focusing on the elderly first instead of the young as previously announced. It was the earliest in the region to receive a vaccine shipment with a Sinovac supply in December.</p>\n<p>Some countries are also involved in vaccine development and manufacturing, a testament to the variety of strategies employed by Southeast Asian nations. Here’s how the region of more than 650 million people is dealing with differing fiscal, demographic and distribution challenges in their vaccination efforts.</p>\n<p>INDONESIA</p>\n<p>STRATEGY:</p>\n<p>Indonesia seeks to vaccinate 181.5 million people -- about two-thirds of the population -- by March 2022 and President Widodo has called on the cabinet to complete the program by end-2021.</p>\n<p>The nation expects its vaccination program to cost more than 73 trillion rupiah ($5.2 billion). It plans to be able to vaccinate 16 million people a month; the initial phase of inoculations will target more than 1.5 million health workers by the end of February.</p>\n<p>The country will offerfree vaccinesto people. With about 13,000 community health centers and 9,000 hospitals across the country, the government said it will be able to complete its targeted vaccination to achieve mass immunity.</p>\n<ul>\n <li>The world’s fourth most populous nation is banking on both Western and Chinese vaccines, ordering 125.5 million doses from Sinovac, 50 million fromAstraZenecaand another 50 million fromNovavax Inc., while developing 57.6 million of its own Merah Putih</li>\n <li>It is set to get as many as 23.1 million AstraZeneca doses from the GAVI alliance, after requesting 108 million free doses from the global vaccine facility</li>\n <li>Talks are also on with Pfizer for 50 million doses and loaned cold storage facilities for the vaccine</li>\n</ul>\n<p>TIMELINE:</p>\n<p>January, 2021: Sinovac</p>\n<p>(More than 784,000 people have received their first dose.)</p>\n<ul>\n <li>President Widodo got his first dose of the Sinovac shot on Jan. 13 along with public and army representatives, which kicked off Indonesia’s inoculation program</li>\n <li>More than 784,000 people have received their first dose as of Feb. 7, with over 139,000 of them completing their second shot</li>\n <li>China’s Sinovac Biotech shipped 3 million doses of vaccines to the country in December; the local food and drug regulator approved them for emergency use in January, and has since also given the nod for its use among theelderly</li>\n <li>Even before the regulator’s approval, the government started distributing the vaccines to its 34 provinces spread across the world’s largest archipelago</li>\n <li>Sinovac has shipped raw material for 55 million doses to be manufactured by Indonesia’s PT Bio Farma so far. The state firm aims to produce 24 million doses a month</li>\n <li>Bio Farma plans to also produce shots for other countries through the Coalition for Epidemic Preparedness Innovations as early as the fourth quarter, according to Indonesia’s state-owned enterprises ministry. Bio Farma will produce 100 million doses a year for CEPI.</li>\n</ul>\n<p>March, 2021: AstraZeneca</p>\n<ul>\n <li>Indonesia willreceivean initial allocation of between 13.7 million and 23.1 million shots of the AstraZeneca vaccine in the first half through the global Covax initiative</li>\n <li>The vaccines will arrive in stages, with 25%-35% by March and the remainder in the second quarter, according to the government. The shots can be used once the WHO approves the AstraZeneca inoculation for emergency use</li>\n <li>Under a separate deal with the company directly, Indonesia will also get the AstraZeneca vaccines delivered in stages starting from as early as April through the first quarter of 2022. The deal also includes the option for the country to purchase an additional 50 million doses.</li>\n</ul>\n<p>MALAYSIA</p>\n<p>STRATEGY:</p>\n<p>Malaysia is spending $504 million to buy enough shots to cover 26.5 million people, or about 80% of its population. It will start vaccinations from February, according to Prime Minister Muhyiddin Yassin. The government aims to get as many people inoculated within a year of getting the first batch of vaccines in February, Science Minister Khairy Jamaluddin said mid-January.</p>\n<p>The first phase of vaccinations, which will begin by end of February and last until April, will focus on inoculating 500,000 frontline workers, followed by the elderly and high-risk groups between April and August. The third leg will run from May through February 2022 for thoseaged18 and above, the prime minister has said.</p>\n<p>The country will have a “slight extra”stockpileof vaccines as only those 18 years old and above will be inoculated. The excess vaccines will be administered to migrant workers, expatriates, and non-Malaysian residents, the cost of which must be borne by their employers.</p>\n<p>Pfizer vaccines will probably be administered to those in urban areas due to the need for ultra-cold storage, while AstraZeneca vaccines will be deployed to rural areas.</p>\n<ul>\n <li>Malaysia hassecured12.8 million doses of the AstraZeneca vaccine through the Covax facility and directly, enough to inoculate 20% of the country’s population, according to the government</li>\n <li>The country has secured 25 million doses of the Pfizer-BioNTech vaccine, enough to cover 39% of the population</li>\n <li>It has also signed agreements for 12 million doses of China’s Sinovac andup to6.4 million doses of Russia’s Sputnik V vaccine</li>\n <li>Solution Group Bhd.signeda deal to supply the Malaysian government with 3.5 million doses of the Recombinant Ad5-nCoV coronavirus vaccine jointly developed by China’sCanSino Biologics Inc.and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences. The purchase is subject to Solution obtaining product registration and market authorization of the vaccine in the country by April</li>\n <li>The government has also been in talks with Moderna and Johnson &amp; Johnson, according to officials</li>\n <li>Malaysia was due to conduct its first vaccine trial involving 3,000 volunteers in late January. It would be a phase-III trial on a vaccine candidate developed by the Institute of Medical Biology Chinese Academy of Medical Sciences</li>\n <li>Malaysia signed an agreement with China inOctoberto be given priority access to Covid-19 vaccines that China develops.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>February, 2021: Pfizer</p>\n<ul>\n <li>The government secured 12.8 million doses from Pfizer-BioNTech SEin a deal signed in late 2020. The country in January agreed to buy an additional 12.2 million doses</li>\n <li>The first batch is due to arrive on Feb. 26</li>\n <li>The agreement with Pfizer is contingent on the vaccine being approved by the U.S. FDA and Malaysia’s regulator. Malaysia’s National Pharmaceutical Regulatory Agency has granted conditional approval for the vaccine, subject to further information from Pfizer, according to a local media report.</li>\n</ul>\n<p>March/April, 2021: Sinovac</p>\n<ul>\n <li>China’s Sinovac signed an agreement to supply 14 million doses to Malaysia, which may be ready for distribution by the end of March</li>\n <li>As part of this deal,Pharmaniaga Bhd.will supply a total of 12 million doses developed by China’s Sinovac Life Sciences Co. starting in April, the health ministry said in January</li>\n</ul>\n<p>1Q 2021: Sputnik V</p>\n<ul>\n <li>Duopharma Co. (M) will supplyup to6.4 million doses of Russia’s Sputnik V vaccines produced by Gamaleya Research Institute toward the end of March</li>\n</ul>\n<p>2Q 2021: AstraZeneca</p>\n<ul>\n <li>Malaysia hassecured6.4 million doses of the AstraZeneca vaccine through the Covax facility, and another 6.4 million directly</li>\n <li>The first batch is expected in the second quarter of 2021</li>\n</ul>\n<p>MYANMAR</p>\n<p>STRATEGY:</p>\n<p>Myanmar began inoculating its nearly 55 million population at theend ofJanuary. Before the military coup in early February, Aung San Suu Kyi’s administration had said frontline health workers and key government officials would be prioritized in the first phase of vaccinations, to be followed by vulnerable groups such as those older than 65 years.</p>\n<p>Myanmar kicked off vaccination for the general public on Feb. 5, less than a week after the coup. Interim President Myint Swe and officials from all ministries with the rank of director or above were also inoculated, along with the elderly in townships with the highest infection rates, according to the health and sports ministry. Suu Kyi, who is under detention at her residence, was also vaccinated on Feb. 6, according to her party officials.</p>\n<p>Myanmar has vowed to inoculate 38.4 million people older than 18 by the end of this year.</p>\n<p>The previous government had also been cooperating with GAVI, the vaccine alliance, to get shots for 20% of its population through the Covax facility. The Southeast Asian nation was also planning to allow the private sector to import World Health Organization-approved vaccines later this year.</p>\n<ul>\n <li>Other than the AstraZeneca deal it has signed, Myanmar also expected vaccines from Chinese developers to arrive in early 2021, with some doses from the Covax facility expected before April 7.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>January, 2021: AstraZeneca</p>\n<p>(At least 103,142 health workers and volunteers have received shots)</p>\n<ul>\n <li>Myanmarordered30 million doses of the AstraZeneca vaccine produced under license bySerum Institute of Indiato vaccinate 15 million people. The country expects the first batch of this order to arrive in the second week of February</li>\n <li>The country expects an additional 27 million doses from the Covax facility from March</li>\n <li>It nevertheless began vaccinations at the end of January, with a separate 1.5 million doses that were donated by India having arrived Jan. 22</li>\n <li>The nation inoculated 103,142 health workers and volunteers as of Feb. 2, official data show.</li>\n</ul>\n<p>PHILIPPINES</p>\n<p>STRATEGY:</p>\n<p></p>\n<p>The Philippines plans to buy 148 million vaccine doses to inoculateup to70 million people this year, or more than half of its population. But it is negotiating for 178 million doses, enough to inoculate 92 million people, to take into account possible delays in deliveries, according to the finance secretary. The government seeks to vaccinate its entire population of more than 100 million by 2023.</p>\n<p>The nation is eyeing 82.5 billion pesos ($1.7 billion) in vaccinepurchasesthat it plans to fund with financing from multilateral agencies, state-owned banks and companies and bilateral sources, vaccine czar Carlito Galvez said.</p>\n<p>A number of mayors in Metropolitan Manila have separately drafted plans to provide shots to their constituents while waiting for guidelines on how local government units can purchase the vaccines.</p>\n<p>Priority for vaccinations will be given to medical frontliners and workers in industries deemed critical, including low-income groups and those identified as at risk.</p>\n<ul>\n <li>The government has signed deals for 30 million doses of the Covovax vaccine from the Serum Institute of India, and for 17 million doses from AstraZeneca</li>\n <li>It is also in talks with Pfizer, Johnson &amp; Johnson, Sinovac Biotech and Russia’s Gamaleya, according to Galvez</li>\n <li>The Philippines has signed apreliminaryagreement with Moderna following negotiations for as many as 20 million vaccine doses. A final supply deal with Moderna will likely be finished in February</li>\n <li>The nation is also expecting to receive fewer doses from the World Health Organization-backed Covax Facility, Galvez said</li>\n <li>China will donate 500,000 coronavirus vaccine doses to the Philippines</li>\n <li>Pfizer and AstraZeneca have been approved for emergency use by the local FDA, while Gamaleya and Sinovac have applied for the same authorization</li>\n <li>India-basedBharat Biotech International Ltd.has applied for emergency use authorization in the Philippines for its coronavirus vaccine, ABS-CBN News reported, citing the Food and Drug Administration head.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>1Q 2021: Sinovac, Sputnik V</p>\n<ul>\n <li>Vaccinations could start as early as the first quarter of 2021 using Sinovac and Russia’s Sputnik V shots, according to Galvez</li>\n <li>Sinovac, Sputnik V are yet to receive the local FDA approval.</li>\n</ul>\n<p>1Q 2021: Pfizer, AstraZeneca</p>\n<ul>\n <li>At least 5.6 million coronavirus vaccine doses produced by Pfizer-BioNTech and AstraZeneca are expected to arrive in the country within the first quarter through the Covax facility</li>\n <li>The country will also receive as early as May 2.6 million doses of AstraZeneca vaccines purchased by local companies which pooled about800 million pesosto buy 3 million shots.</li>\n</ul>\n<p>SINGAPORE</p>\n<p>STRATEGY:</p>\n<p>The city-state has set aside roughly S$1 billion ($750 million) for vaccines, tapping the likes ofArcturus Therapeutics Holdings Inc.,Moderna, Pfizer and Sinovac for supplies. It estimates it should haveenoughfor its around 5.5 million-strong population by the third quarter of 2021.</p>\n<p>The city-state is prioritizinghealthcareworkers, the elderly and those in jobs or settings where risk of a super-spreading event is high -- such as the construction, marine and process sector, including migrant workers. For the elderly, it began with seniorsaged70 and above.</p>\n<p>Singapore aims to vaccinate the entire adult population, though this will be voluntary. Vaccines will be free for all Singaporeans and long-term residents. It is setting up vaccination centers across the island.</p>\n<p>TIMELINE:</p>\n<p>December, 2020: Pfizer</p>\n<p>(More than 175,000 people given first dose)</p>\n<ul>\n <li>Singapore started vaccinations on Dec. 30, 2020</li>\n <li>Prime Minister Lee Hsien Loong got a first dose of the vaccine on Jan. 8, making him the first member of cabinet to get the coronavirus vaccine shot</li>\n <li>The government said more than 175,000 people have received their first dose of the Covid-19 vaccine as of Feb. 2. Roughly 6,000 have received their second vaccine dose</li>\n <li>The city-state received its first shipment of the Pfizer-BioNTech vaccine on Dec. 21</li>\n <li>Those who have received shots include staff working inhealthcare, frontline and essential services, as well as staff and senior citizens in nursing homes. Some employees at the National Centre for Infectious Diseases have also received their second dose.</li>\n <li>Pilot vaccinations for senior citizensstartedJan. 27.</li>\n</ul>\n<p>March, 2021: Moderna</p>\n<ul>\n <li>Singapore granted interim authorization in February for Moderna’s Covid-19 vaccine to be used in the city-state. Moderna is the second vaccine to be authorized in Singapore</li>\n <li>Singapore’s Ministry of Health said that the country will roll out the Moderna vaccine for individualsaged18 years and above when shipments of the vaccine arrive</li>\n <li>If there are no disruptions to the schedule, the first shipment should arrive around March.</li>\n</ul>\n<p>Early 2021: Arcturus</p>\n<ul>\n <li>Arcturus and Singapore’s Economic Development Board have entered into a supply agreement for the right to buy the ARCT-021 vaccine</li>\n <li>Arcturus may ship the first batch of the Covid-19 vaccine it’s developing with local scientists early 2021</li>\n <li>Results so far show that the vaccine could be effective as a single dose, the Straits Times reported, citing a professor who co-developed the vaccine with Arcturus.</li>\n</ul>\n<p>THAILAND</p>\n<p>STRATEGY:</p>\n<p>Thailand wants to inoculate about 50% of its population by the end of this year.</p>\n<p>It has previously said it will allow private companies and hospitals to import and sell Covid-19 vaccinations as long as those shots have been approved by the nation’s Food and Drug Administration.</p>\n<p>Thailand’s health regulatorendorsedAstraZeneca’s vaccine for emergency use, the health minister said on Jan. 21. It’s the first to win approval in Thailand, which also has ordered shots developed by China’s Sinovac Biotech. Johnson &amp; Johnson has begun the process of seeking domestic approval for its vaccine.</p>\n<p>The Southeast Asian nation plans to distribute shots free of cost, while the imports by private firms would allow those who can afford to pay for inoculations along with non-Thais an alternative pathway to get shots. It won’t procure vaccines through the WHO-backed Covax program for now because theconditionsare too strict.</p>\n<ul>\n <li>The government has so far approved plans to purchase a total of 63 million doses, and the National Vaccine Institute is in talks with several manufacturers for additional supplies for delivery as early as the first quarter. These include 2 million doses from Sinovac and 61 million doses from AstraZeneca</li>\n <li>Not wanting to rely solely on inoculations from abroad, Thailand is also developing its own anti-coronavirus shot</li>\n</ul>\n<p>TIMELINE:</p>\n<p>February, 2021: Sinovac</p>\n<ul>\n <li>The country has said it plans to roll out 200,000 doses of Sinovac vaccines in February, 800,000 in March, and 1 million in April</li>\n</ul>\n<p>February, 2021: AstraZeneca</p>\n<ul>\n <li>Thailand has an advance agreement with AstraZeneca to secure Covid-19 vaccines, which are expected to be distributed by mid-2021, the prime minister has said</li>\n <li>The government expects 50,000 doses to arrive in February</li>\n <li>The government has ordered 61 million shots. The regulatory nod already given will also open the door for imports by private Thai companies for administering the doses to people who can afford to pay</li>\n <li>The country said early January it plans to roll out locally-produced AstraZeneca vaccines in May</li>\n <li>Under agreement with AstraZeneca, Siam Bioscience will produce vaccines at its facilities, and Thailand will receive technology transfer</li>\n <li>Thailand’s prime minister has said the country will supply coronavirus vaccines at “reasonable prices” to Myanmar, Laos, Cambodia and Vietnam when it begins production.</li>\n</ul>\n<p>VIETNAM</p>\n<p>STRATEGY:</p>\n<p>Vietnam is working on developing vaccines and will collaborate with suppliers when doses are available, according to a spokeswoman at the foreign affairs ministry.</p>\n<ul>\n <li>It signed a deal with AstraZeneca to acquire about 30 million doses of the Covid-19 vaccine, Deputy Health Minister Truong Quoc Cuong said during a government briefing in January</li>\n <li>It has also been negotiating to buy vaccines from Pfizer and companies from Russia and China, Cuong said</li>\n <li>Vietnam has four companies and institutes working on developing vaccines.Nanogen Pharmaceutical Biotechnologybegan its human vaccine trials Dec. 17. The Institute of Vaccines and Medical Biologicals started human trials Jan. 21, according to the health ministry.</li>\n</ul>\n<p>TIMELINE:</p>\n<p>1Q 2021: AstraZeneca</p>\n<ul>\n <li>Under the deal with AstraZeneca for about 30 million doses, Vietnam expects to receive vaccines each quarter this year, the deputy health minister said Jan. 4</li>\n <li>In addition, Vietnam expects to receive between 4.9 million to 8.25 million AstraZeneca vaccine doses through the WHO-backed Covax program during the first and second quarters, according to a government posting citing Covax.</li>\n</ul>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Gets Added to Southeast Asia’s Vaccine Arsenal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Gets Added to Southeast Asia’s Vaccine Arsenal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-08 17:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.\nShots by ...</p>\n\n<a href=\"http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://bloomberg.com/news/articles/2021-02-08/moderna-gets-added-to-arsenal-southeast-asia-vaccine-tracker?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126813487","content_text":"Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.\nShots by AstraZeneca Plc,Pfizer Inc.-BioNTech SEandSinovac Biotech Ltd.have also been approved by at least one country in the region as inoculations roll out. China and India are giving somefreevaccines to countries like the Philippines, Myanmar and Cambodia.\nIndonesia, Southeast Asia’s biggest and most populous economy,startedits coronavirus vaccination program on Jan. 13, with President Joko Widodo taking thefirst Sinovac jab. More than 784,000 people have received their first dose.\nWealthier but smaller Singapore -- the first in Southeast Asia to start an official Covid-19 vaccination program -- began inoculatinghealthcareworkers with the Pfizer shot on Dec. 30 and has given the first shot to more than 175,000 people since then. Its prime minister got his first dose on Jan. 8 and has also received his second shot.\nStrategies are evolving across the region as different supply deals are sealed. In the Philippines, President Rodrigo Duterte has said he will take a Russian or Chinese vaccine, but his government’s first approval was for the Pfizer shot.\nIndonesia, which is battling the worst outbreak in Southeast Asia, ended 2020 by switching up who’s on its priority list for shots -- focusing on the elderly first instead of the young as previously announced. It was the earliest in the region to receive a vaccine shipment with a Sinovac supply in December.\nSome countries are also involved in vaccine development and manufacturing, a testament to the variety of strategies employed by Southeast Asian nations. Here’s how the region of more than 650 million people is dealing with differing fiscal, demographic and distribution challenges in their vaccination efforts.\nINDONESIA\nSTRATEGY:\nIndonesia seeks to vaccinate 181.5 million people -- about two-thirds of the population -- by March 2022 and President Widodo has called on the cabinet to complete the program by end-2021.\nThe nation expects its vaccination program to cost more than 73 trillion rupiah ($5.2 billion). It plans to be able to vaccinate 16 million people a month; the initial phase of inoculations will target more than 1.5 million health workers by the end of February.\nThe country will offerfree vaccinesto people. With about 13,000 community health centers and 9,000 hospitals across the country, the government said it will be able to complete its targeted vaccination to achieve mass immunity.\n\nThe world’s fourth most populous nation is banking on both Western and Chinese vaccines, ordering 125.5 million doses from Sinovac, 50 million fromAstraZenecaand another 50 million fromNovavax Inc., while developing 57.6 million of its own Merah Putih\nIt is set to get as many as 23.1 million AstraZeneca doses from the GAVI alliance, after requesting 108 million free doses from the global vaccine facility\nTalks are also on with Pfizer for 50 million doses and loaned cold storage facilities for the vaccine\n\nTIMELINE:\nJanuary, 2021: Sinovac\n(More than 784,000 people have received their first dose.)\n\nPresident Widodo got his first dose of the Sinovac shot on Jan. 13 along with public and army representatives, which kicked off Indonesia’s inoculation program\nMore than 784,000 people have received their first dose as of Feb. 7, with over 139,000 of them completing their second shot\nChina’s Sinovac Biotech shipped 3 million doses of vaccines to the country in December; the local food and drug regulator approved them for emergency use in January, and has since also given the nod for its use among theelderly\nEven before the regulator’s approval, the government started distributing the vaccines to its 34 provinces spread across the world’s largest archipelago\nSinovac has shipped raw material for 55 million doses to be manufactured by Indonesia’s PT Bio Farma so far. The state firm aims to produce 24 million doses a month\nBio Farma plans to also produce shots for other countries through the Coalition for Epidemic Preparedness Innovations as early as the fourth quarter, according to Indonesia’s state-owned enterprises ministry. Bio Farma will produce 100 million doses a year for CEPI.\n\nMarch, 2021: AstraZeneca\n\nIndonesia willreceivean initial allocation of between 13.7 million and 23.1 million shots of the AstraZeneca vaccine in the first half through the global Covax initiative\nThe vaccines will arrive in stages, with 25%-35% by March and the remainder in the second quarter, according to the government. The shots can be used once the WHO approves the AstraZeneca inoculation for emergency use\nUnder a separate deal with the company directly, Indonesia will also get the AstraZeneca vaccines delivered in stages starting from as early as April through the first quarter of 2022. The deal also includes the option for the country to purchase an additional 50 million doses.\n\nMALAYSIA\nSTRATEGY:\nMalaysia is spending $504 million to buy enough shots to cover 26.5 million people, or about 80% of its population. It will start vaccinations from February, according to Prime Minister Muhyiddin Yassin. The government aims to get as many people inoculated within a year of getting the first batch of vaccines in February, Science Minister Khairy Jamaluddin said mid-January.\nThe first phase of vaccinations, which will begin by end of February and last until April, will focus on inoculating 500,000 frontline workers, followed by the elderly and high-risk groups between April and August. The third leg will run from May through February 2022 for thoseaged18 and above, the prime minister has said.\nThe country will have a “slight extra”stockpileof vaccines as only those 18 years old and above will be inoculated. The excess vaccines will be administered to migrant workers, expatriates, and non-Malaysian residents, the cost of which must be borne by their employers.\nPfizer vaccines will probably be administered to those in urban areas due to the need for ultra-cold storage, while AstraZeneca vaccines will be deployed to rural areas.\n\nMalaysia hassecured12.8 million doses of the AstraZeneca vaccine through the Covax facility and directly, enough to inoculate 20% of the country’s population, according to the government\nThe country has secured 25 million doses of the Pfizer-BioNTech vaccine, enough to cover 39% of the population\nIt has also signed agreements for 12 million doses of China’s Sinovac andup to6.4 million doses of Russia’s Sputnik V vaccine\nSolution Group Bhd.signeda deal to supply the Malaysian government with 3.5 million doses of the Recombinant Ad5-nCoV coronavirus vaccine jointly developed by China’sCanSino Biologics Inc.and Beijing Institute of Biotechnology under the Academy of Military Medical Sciences. The purchase is subject to Solution obtaining product registration and market authorization of the vaccine in the country by April\nThe government has also been in talks with Moderna and Johnson & Johnson, according to officials\nMalaysia was due to conduct its first vaccine trial involving 3,000 volunteers in late January. It would be a phase-III trial on a vaccine candidate developed by the Institute of Medical Biology Chinese Academy of Medical Sciences\nMalaysia signed an agreement with China inOctoberto be given priority access to Covid-19 vaccines that China develops.\n\nTIMELINE:\nFebruary, 2021: Pfizer\n\nThe government secured 12.8 million doses from Pfizer-BioNTech SEin a deal signed in late 2020. The country in January agreed to buy an additional 12.2 million doses\nThe first batch is due to arrive on Feb. 26\nThe agreement with Pfizer is contingent on the vaccine being approved by the U.S. FDA and Malaysia’s regulator. Malaysia’s National Pharmaceutical Regulatory Agency has granted conditional approval for the vaccine, subject to further information from Pfizer, according to a local media report.\n\nMarch/April, 2021: Sinovac\n\nChina’s Sinovac signed an agreement to supply 14 million doses to Malaysia, which may be ready for distribution by the end of March\nAs part of this deal,Pharmaniaga Bhd.will supply a total of 12 million doses developed by China’s Sinovac Life Sciences Co. starting in April, the health ministry said in January\n\n1Q 2021: Sputnik V\n\nDuopharma Co. (M) will supplyup to6.4 million doses of Russia’s Sputnik V vaccines produced by Gamaleya Research Institute toward the end of March\n\n2Q 2021: AstraZeneca\n\nMalaysia hassecured6.4 million doses of the AstraZeneca vaccine through the Covax facility, and another 6.4 million directly\nThe first batch is expected in the second quarter of 2021\n\nMYANMAR\nSTRATEGY:\nMyanmar began inoculating its nearly 55 million population at theend ofJanuary. Before the military coup in early February, Aung San Suu Kyi’s administration had said frontline health workers and key government officials would be prioritized in the first phase of vaccinations, to be followed by vulnerable groups such as those older than 65 years.\nMyanmar kicked off vaccination for the general public on Feb. 5, less than a week after the coup. Interim President Myint Swe and officials from all ministries with the rank of director or above were also inoculated, along with the elderly in townships with the highest infection rates, according to the health and sports ministry. Suu Kyi, who is under detention at her residence, was also vaccinated on Feb. 6, according to her party officials.\nMyanmar has vowed to inoculate 38.4 million people older than 18 by the end of this year.\nThe previous government had also been cooperating with GAVI, the vaccine alliance, to get shots for 20% of its population through the Covax facility. The Southeast Asian nation was also planning to allow the private sector to import World Health Organization-approved vaccines later this year.\n\nOther than the AstraZeneca deal it has signed, Myanmar also expected vaccines from Chinese developers to arrive in early 2021, with some doses from the Covax facility expected before April 7.\n\nTIMELINE:\nJanuary, 2021: AstraZeneca\n(At least 103,142 health workers and volunteers have received shots)\n\nMyanmarordered30 million doses of the AstraZeneca vaccine produced under license bySerum Institute of Indiato vaccinate 15 million people. The country expects the first batch of this order to arrive in the second week of February\nThe country expects an additional 27 million doses from the Covax facility from March\nIt nevertheless began vaccinations at the end of January, with a separate 1.5 million doses that were donated by India having arrived Jan. 22\nThe nation inoculated 103,142 health workers and volunteers as of Feb. 2, official data show.\n\nPHILIPPINES\nSTRATEGY:\n\nThe Philippines plans to buy 148 million vaccine doses to inoculateup to70 million people this year, or more than half of its population. But it is negotiating for 178 million doses, enough to inoculate 92 million people, to take into account possible delays in deliveries, according to the finance secretary. The government seeks to vaccinate its entire population of more than 100 million by 2023.\nThe nation is eyeing 82.5 billion pesos ($1.7 billion) in vaccinepurchasesthat it plans to fund with financing from multilateral agencies, state-owned banks and companies and bilateral sources, vaccine czar Carlito Galvez said.\nA number of mayors in Metropolitan Manila have separately drafted plans to provide shots to their constituents while waiting for guidelines on how local government units can purchase the vaccines.\nPriority for vaccinations will be given to medical frontliners and workers in industries deemed critical, including low-income groups and those identified as at risk.\n\nThe government has signed deals for 30 million doses of the Covovax vaccine from the Serum Institute of India, and for 17 million doses from AstraZeneca\nIt is also in talks with Pfizer, Johnson & Johnson, Sinovac Biotech and Russia’s Gamaleya, according to Galvez\nThe Philippines has signed apreliminaryagreement with Moderna following negotiations for as many as 20 million vaccine doses. A final supply deal with Moderna will likely be finished in February\nThe nation is also expecting to receive fewer doses from the World Health Organization-backed Covax Facility, Galvez said\nChina will donate 500,000 coronavirus vaccine doses to the Philippines\nPfizer and AstraZeneca have been approved for emergency use by the local FDA, while Gamaleya and Sinovac have applied for the same authorization\nIndia-basedBharat Biotech International Ltd.has applied for emergency use authorization in the Philippines for its coronavirus vaccine, ABS-CBN News reported, citing the Food and Drug Administration head.\n\nTIMELINE:\n1Q 2021: Sinovac, Sputnik V\n\nVaccinations could start as early as the first quarter of 2021 using Sinovac and Russia’s Sputnik V shots, according to Galvez\nSinovac, Sputnik V are yet to receive the local FDA approval.\n\n1Q 2021: Pfizer, AstraZeneca\n\nAt least 5.6 million coronavirus vaccine doses produced by Pfizer-BioNTech and AstraZeneca are expected to arrive in the country within the first quarter through the Covax facility\nThe country will also receive as early as May 2.6 million doses of AstraZeneca vaccines purchased by local companies which pooled about800 million pesosto buy 3 million shots.\n\nSINGAPORE\nSTRATEGY:\nThe city-state has set aside roughly S$1 billion ($750 million) for vaccines, tapping the likes ofArcturus Therapeutics Holdings Inc.,Moderna, Pfizer and Sinovac for supplies. It estimates it should haveenoughfor its around 5.5 million-strong population by the third quarter of 2021.\nThe city-state is prioritizinghealthcareworkers, the elderly and those in jobs or settings where risk of a super-spreading event is high -- such as the construction, marine and process sector, including migrant workers. For the elderly, it began with seniorsaged70 and above.\nSingapore aims to vaccinate the entire adult population, though this will be voluntary. Vaccines will be free for all Singaporeans and long-term residents. It is setting up vaccination centers across the island.\nTIMELINE:\nDecember, 2020: Pfizer\n(More than 175,000 people given first dose)\n\nSingapore started vaccinations on Dec. 30, 2020\nPrime Minister Lee Hsien Loong got a first dose of the vaccine on Jan. 8, making him the first member of cabinet to get the coronavirus vaccine shot\nThe government said more than 175,000 people have received their first dose of the Covid-19 vaccine as of Feb. 2. Roughly 6,000 have received their second vaccine dose\nThe city-state received its first shipment of the Pfizer-BioNTech vaccine on Dec. 21\nThose who have received shots include staff working inhealthcare, frontline and essential services, as well as staff and senior citizens in nursing homes. Some employees at the National Centre for Infectious Diseases have also received their second dose.\nPilot vaccinations for senior citizensstartedJan. 27.\n\nMarch, 2021: Moderna\n\nSingapore granted interim authorization in February for Moderna’s Covid-19 vaccine to be used in the city-state. Moderna is the second vaccine to be authorized in Singapore\nSingapore’s Ministry of Health said that the country will roll out the Moderna vaccine for individualsaged18 years and above when shipments of the vaccine arrive\nIf there are no disruptions to the schedule, the first shipment should arrive around March.\n\nEarly 2021: Arcturus\n\nArcturus and Singapore’s Economic Development Board have entered into a supply agreement for the right to buy the ARCT-021 vaccine\nArcturus may ship the first batch of the Covid-19 vaccine it’s developing with local scientists early 2021\nResults so far show that the vaccine could be effective as a single dose, the Straits Times reported, citing a professor who co-developed the vaccine with Arcturus.\n\nTHAILAND\nSTRATEGY:\nThailand wants to inoculate about 50% of its population by the end of this year.\nIt has previously said it will allow private companies and hospitals to import and sell Covid-19 vaccinations as long as those shots have been approved by the nation’s Food and Drug Administration.\nThailand’s health regulatorendorsedAstraZeneca’s vaccine for emergency use, the health minister said on Jan. 21. It’s the first to win approval in Thailand, which also has ordered shots developed by China’s Sinovac Biotech. Johnson & Johnson has begun the process of seeking domestic approval for its vaccine.\nThe Southeast Asian nation plans to distribute shots free of cost, while the imports by private firms would allow those who can afford to pay for inoculations along with non-Thais an alternative pathway to get shots. It won’t procure vaccines through the WHO-backed Covax program for now because theconditionsare too strict.\n\nThe government has so far approved plans to purchase a total of 63 million doses, and the National Vaccine Institute is in talks with several manufacturers for additional supplies for delivery as early as the first quarter. These include 2 million doses from Sinovac and 61 million doses from AstraZeneca\nNot wanting to rely solely on inoculations from abroad, Thailand is also developing its own anti-coronavirus shot\n\nTIMELINE:\nFebruary, 2021: Sinovac\n\nThe country has said it plans to roll out 200,000 doses of Sinovac vaccines in February, 800,000 in March, and 1 million in April\n\nFebruary, 2021: AstraZeneca\n\nThailand has an advance agreement with AstraZeneca to secure Covid-19 vaccines, which are expected to be distributed by mid-2021, the prime minister has said\nThe government expects 50,000 doses to arrive in February\nThe government has ordered 61 million shots. The regulatory nod already given will also open the door for imports by private Thai companies for administering the doses to people who can afford to pay\nThe country said early January it plans to roll out locally-produced AstraZeneca vaccines in May\nUnder agreement with AstraZeneca, Siam Bioscience will produce vaccines at its facilities, and Thailand will receive technology transfer\nThailand’s prime minister has said the country will supply coronavirus vaccines at “reasonable prices” to Myanmar, Laos, Cambodia and Vietnam when it begins production.\n\nVIETNAM\nSTRATEGY:\nVietnam is working on developing vaccines and will collaborate with suppliers when doses are available, according to a spokeswoman at the foreign affairs ministry.\n\nIt signed a deal with AstraZeneca to acquire about 30 million doses of the Covid-19 vaccine, Deputy Health Minister Truong Quoc Cuong said during a government briefing in January\nIt has also been negotiating to buy vaccines from Pfizer and companies from Russia and China, Cuong said\nVietnam has four companies and institutes working on developing vaccines.Nanogen Pharmaceutical Biotechnologybegan its human vaccine trials Dec. 17. The Institute of Vaccines and Medical Biologicals started human trials Jan. 21, according to the health ministry.\n\nTIMELINE:\n1Q 2021: AstraZeneca\n\nUnder the deal with AstraZeneca for about 30 million doses, Vietnam expects to receive vaccines each quarter this year, the deputy health minister said Jan. 4\nIn addition, Vietnam expects to receive between 4.9 million to 8.25 million AstraZeneca vaccine doses through the WHO-backed Covax program during the first and second quarters, according to a government posting citing Covax.","news_type":1},"isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":356963142,"gmtCreate":1616749184486,"gmtModify":1634524210055,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[比心]&nbsp;[比心]&nbsp;[比心]&nbsp;","listText":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[比心]&nbsp;[比心]&nbsp;[比心]&nbsp;","text":"Wow!! All ready to rocket now!! Buy! I’m buying! Who else? [财迷] [财迷] [财迷] [比心] [比心] [比心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/356963142","repostId":"1147585149","repostType":2,"isVote":1,"tweetType":1,"viewCount":437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603155467,"gmtCreate":1638378206090,"gmtModify":1638378206697,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It’s in the app. Under “analysis”","listText":"It’s in the app. Under “analysis”","text":"It’s in the app. Under “analysis”","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603155467","repostId":"603152283","repostType":1,"repost":{"id":603152283,"gmtCreate":1638378053907,"gmtModify":1638378054019,"author":{"id":"3574753638076287","authorId":"3574753638076287","name":"Ceddy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>can someone analysis the short margin and short rate?","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>can someone analysis the short margin and short rate?","text":"$Tiger Brokers(TIGR)$can someone analysis the short margin and short rate?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603152283","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":831697045,"gmtCreate":1629309343587,"gmtModify":1633685797077,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"是的","listText":"是的","text":"是的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831697045","repostId":"831845481","repostType":1,"repost":{"id":831845481,"gmtCreate":1629303917443,"gmtModify":1633685816047,"author":{"id":"3561619960620770","authorId":"3561619960620770","name":"炒股就是炒预期","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 今晚不跳，明天必上17","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 今晚不跳，明天必上17","text":"$老虎证券(TIGR)$ 今晚不跳，明天必上17","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831845481","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":340536334,"gmtCreate":1617428891428,"gmtModify":1634520988821,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Bought!","listText":"[得意]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Bought!","text":"[得意] //@JLX:Bought!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/340536334","repostId":"1113135434","repostType":4,"isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":357890286,"gmtCreate":1617253722945,"gmtModify":1634521781400,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Check out all stocks related to Ev&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;//<a href=\"https://laohu8.com/U/3575719904277494\">@JLX</a>:Check out all stocks related to Ev&nbsp;","text":"[财迷] [财迷] [财迷] [财迷] //@JLX:Check out all stocks related to Ev","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/357890286","repostId":"1138291357","repostType":4,"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":389262038,"gmtCreate":1612778867224,"gmtModify":1703764880427,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389262038","repostId":"1126813487","repostType":4,"isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}